{
    "clinical_study": {
        "@rank": "18320", 
        "arm_group": [
            {
                "arm_group_label": "control group", 
                "arm_group_type": "No Intervention", 
                "description": "The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans."
            }, 
            {
                "arm_group_label": "Immuncell-LC group", 
                "arm_group_type": "Experimental", 
                "description": "The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times)."
            }
        ], 
        "brief_summary": {
            "textblock": "\"Immuncell-LC\" in aspects of therapeutic efficacy and safety when administered with Nexavar\n      to advanced Hepatocellular carcinoma patients when compared with the control group who did\n      not receive administration of the drug."
        }, 
        "brief_title": "Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hcc", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  primary outcome Compare clinical efficacy of group treated with cell therapeutic\n           Immuncell-LC evaluated by progression free survival with that of untreated group\n\n        -  secondary outcome compare clinical efficacy of group treated with Immuncell-LC, a drug\n           for treating advanced hepatocellular carcinoma evaluated by overall survival, disease\n           control rate, changes of Alpha Feto Protein(AFP) figures from baseline to the last\n           observation date and that of untreated group and evaluate adverse reactions, clinical\n           pathological tests and its safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have consented to the study by providing signature of self,  guardian or\n             legal representative\n\n          -  The patient is more than 20 and less than 80 years old\n\n          -  The patient is diagnosed as hepatocellular carcinoma by pathological/radiological\n             test and in the stage of III or IV\n\n          -  Child-Pugh Score should be A\n\n          -  ECOG Performance Status (ECOG-PS) is less than 2 or equal to\n\n          -  Patients who receiving or ready for Nexavar treatment\n\n          -  Patients who satisfy the following conditions of the blood test and kidney function\n             test\n\n               -  Absolute granulocyte count is bigger than 1,000/\u00b5L\n\n               -  Hemoglobin is bigger than 8.5 g/dL\n\n               -  Platelet count is bigger than 5x10^10/L\n\n               -  Blood Urea Nitrogen(BUN) or Creatinine 1.5xupper normal limit\n\n        Exclusion Criteria:\n\n          -  Patients who are immune deficient or have a history of auto-immune diseases (Ex.\n             Rheumatoid Arthritism, Systemic Lupus Erythematosus, Vasculitis, Multiple sclerosis,\n             Adolescent Insulin-Dependent Diabetes Mellitus, etc.)\n\n          -  Patients who have a history of malignant tumors in the recent 5 years prior to the\n             study with the exception of basal cell carcinoma, local prostate cancer, and cervical\n             cancer, liver cancer.\n\n          -  Patients who had anti-cancer medication before the study with  the exception of\n             Nexavar\n\n          -  Patients who has serious dysfunction in other organs by sub-investigator's opinion\n\n          -  Patients has serious allergic-history by sub-investigator's opinion\n\n          -  Patients has serious mental disease sub-investigator's opinion\n\n          -  Pregnant women, nursing mother of having intention of being pregnant during the study\n\n          -  Patients who participated in other clinical trial within 4 weeks before this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897610", 
            "org_study_id": "ILC-IIT-04"
        }, 
        "intervention": {
            "arm_group_label": "Immuncell-LC group", 
            "description": "intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour", 
            "intervention_name": "Immuncell-LC", 
            "intervention_type": "Drug", 
            "other_name": "activated T lymphocyte"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Immuncell-LC, advanced hepatocellular carcinoma", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jin@inha.ac.kr", 
                    "last_name": "Jin-Woo Lee, MD, PhD", 
                    "phone": "82-32-890-2548"
                }, 
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "400-711"
                    }, 
                    "name": "Inha University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jin-Woo Lee, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "umsh@korea.ac.kr", 
                    "last_name": "Soon Ho Um, MD, PhD", 
                    "phone": "82-2-920-5019"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "136-750"
                    }, 
                    "name": "Korea University Anam Hospital"
                }, 
                "investigator": {
                    "last_name": "Soon Ho Um, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dyk1025@yuhs.ac", 
                    "last_name": "Do Young Kim, MD, PhD", 
                    "phone": "82-2-2228-1992"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Yonsei University Health System"
                }, 
                "investigator": {
                    "last_name": "Do Young Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jychoi@catholic.as.kr", 
                    "last_name": "Jong Young Choi, MD, PhD", 
                    "phone": "02-2-2258-7565"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "The Catholic University of Korea, Seoul ST. Mary's Hospital"
                }, 
                "investigator": {
                    "last_name": "Jong Young Choi, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "umsh@korea.ac.kr", 
            "last_name": "Soon Ho Um, MD. PhD", 
            "phone": "82-2-920-5019"
        }, 
        "overall_official": {
            "affiliation": "Korea University Anam Hospital", 
            "last_name": "Soon Ho Um, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CT, PET-CT, MRI", 
            "measure": "To assess progression-free survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "reference": [
            {
                "PMID": "12394214", 
                "citation": "Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S109-14. Review."
            }, 
            {
                "PMID": "15195890", 
                "citation": "Ganne-Carri\u00e9 N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):275-81. Review."
            }, 
            {
                "PMID": "19095497", 
                "citation": "Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. Epub 2008 Dec 16."
            }, 
            {
                "PMID": "18650514", 
                "citation": "Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90."
            }, 
            {
                "PMID": "17953709", 
                "citation": "Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008 Jan;99(1):159-65. Epub 2007 Oct 22."
            }, 
            {
                "PMID": "18846384", 
                "citation": "Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol. 2009 Apr;135(4):617-25. doi: 10.1007/s00432-008-0496-x. Epub 2008 Oct 10."
            }, 
            {
                "PMID": "11022927", 
                "citation": "Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000 Sep 2;356(9232):802-7. Erratum in: Lancet 2000 Nov 11;356(9242):1690."
            }, 
            {
                "PMID": "17996690", 
                "citation": "Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y, Han SB. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 2007 Dec 15;7(13):1793-801. Epub 2007 Aug 31."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897610"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To assess the overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "to determine response rate (CR, PR, SD rate) from the baseline to the late observation date using mRECIST", 
                "measure": "To evaluate the Disease control rate", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "analysing the changes of AFP before and after combination Nexavar plus Immuncell-LC", 
                "measure": "To assess the changes of Alpha Feto Protein(AFP)figures from baseline to the last observation date", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Green Cross Cell Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Green Cross Cell Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}